Search Medical Condition
Please enter condition
Please choose location from dropdown

Wellesley, Massachusetts Clinical Trials

A listing of Wellesley, Massachusetts clinical trials actively recruiting patient volunteers.

RESULTS

Found (235) clinical trials

785nm Picosecond Laser for Treatment of Benign Pigmented Lesions

This study is a prospective clinical study to demonstrate the safety and efficacy of the PicoWay device for benign pigmented lesion treatment. Up to a total of 60 healthy candidates, who are seeking treatment/clearance of benign pigmented lesions, will be enrolled at up to 3 participating study sites. Subjects will ...

Phase N/A

5.69 miles

Learn More »

VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation

The primary objective of this trial is to collect data from the use of VELOS in clinical practice under a wide range of treatment parameters variability including RF energy, laser fluence, and laser pulse duration for treating each of the vascular disorders. This will be conducted by documenting the physician ...

Phase N/A

5.69 miles

Learn More »

PicoWay 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles

Subjects will receive up to 4 study treatments with the PicoWay 730 nm laser wavelength, PicoWay1064nm fractional handpiece and/or PicoWay 1064nm fractional handpiece for treatment of benign pigmented lesions or wrinkles. Subjects will return for three follow-up visit evaluations 1-month, 2-months and 3-months post final study treatment. Primary efficacy assessed ...

Phase N/A

5.69 miles

Learn More »

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The ...

Phase

5.79 miles

Learn More »

Long Term Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, 12-AVR-131, or 17-AVP-786-305. Participants will be enrolled in the study for approximately 56 weeks (participants who have a follow-up visit 3 months after the last dose of treatment will be enrolled for approximately 64 weeks). Approximately 1000 participants will be enrolled at approximately ...

Phase

5.79 miles

Learn More »

Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Study to assess the long term safety and tolerability of ACT-541468 in adult and elderly subjects suffering from difficulties to sleep

Phase

5.79 miles

Learn More »

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.

Phase

5.79 miles

Learn More »

Study of Tolerability Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

Subjects will be enrolled in two Cohorts (N=10 each, enrolled sequentially), and each will assess two different dose levels (randomly assigned). Based on initial outcomes in Cohort 1 at Interim Analysis, the doses for Cohort 2 will be escalated or decreased. Subjects will participate in 1 year (48 weeks) of ...

Phase N/A

5.79 miles

Learn More »

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.

Phase

5.79 miles

Learn More »

GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 oral capsules in subjects with probable AD dementia according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. The study will enroll approximately 573 generally healthy male and female ...

Phase

5.79 miles

Learn More »